Literature DB >> 22889593

The genetics of type I interferon in systemic lupus erythematosus.

Paola G Bronson1, Christina Chaivorapol, Ward Ortmann, Timothy W Behrens, Robert R Graham.   

Abstract

The discovery that type I interferon (IFN)-inducible genes were strongly upregulated in peripheral blood in SLE over a decade ago sparked interest in understanding the relationship between type I IFN and SLE. Genome-wide association studies provide strong genetic evidence that type I IFNs are important for SLE risk. Of 47 genetic variants associated with SLE, over half (27/47, 57%) can be linked to type I IFN production or signaling. The recent identification of single gene mutations for disorders that share features with SLE--Aicardi-Goutières syndrome, chilblain lupus, and spondyloenchondrodysplasia--provide additional support for the hypothesis that type I IFNs are central drivers of SLE pathogenesis. These insights provide significant focus for efforts to tackle SLE therapeutically.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22889593     DOI: 10.1016/j.coi.2012.07.008

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  60 in total

1.  Type I IFN Is Necessary and Sufficient for Inflammation-Induced Red Blood Cell Alloimmunization in Mice.

Authors:  David R Gibb; Jingchun Liu; Prabitha Natarajan; Manjula Santhanakrishnan; David J Madrid; Stephanie C Eisenbarth; James C Zimring; Akiko Iwasaki; Jeanne E Hendrickson
Journal:  J Immunol       Date:  2017-06-19       Impact factor: 5.422

2.  Type I interferon controls propagation of long interspersed element-1.

Authors:  Qiujing Yu; Christopher J Carbone; Yuliya V Katlinskaya; Hui Zheng; Ke Zheng; Mengcheng Luo; P Jeremy Wang; Roger A Greenberg; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2015-02-25       Impact factor: 5.157

Review 3.  Are toll-like receptors potential drug targets for atherosclerosis? Evidence from genetic studies to date.

Authors:  Christopher P Nelson; Clett Erridge
Journal:  Immunogenetics       Date:  2018-10-16       Impact factor: 2.846

4.  Interferon-α Triggers Autoimmune Thyroid Diseases via Lysosomal-Dependent Degradation of Thyroglobulin.

Authors:  Larissa C Faustino; Angela Lombardi; Julio Madrigal-Matute; Randall P Owen; Steven K Libutti; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

Review 5.  The Post-GWAS Era: How to Validate the Contribution of Gene Variants in Lupus.

Authors:  Adam J Fike; Irina Elcheva; Ziaur S M Rahman
Journal:  Curr Rheumatol Rep       Date:  2019-01-23       Impact factor: 4.592

6.  Dosage of X-linked Toll-like receptor 8 determines gender differences in the development of systemic lupus erythematosus.

Authors:  Benjamin R Umiker; Shauna Andersson; Luis Fernandez; Parimal Korgaokar; Amma Larbi; Monika Pilichowska; Craig C Weinkauf; Henry H Wortis; John F Kearney; Thereza Imanishi-Kari
Journal:  Eur J Immunol       Date:  2014-03-20       Impact factor: 5.532

Review 7.  The Roles of Orphan G Protein-Coupled Receptors in Autoimmune Diseases.

Authors:  Mingming Zhao; Zheyu Wang; Ming Yang; Yan Ding; Ming Zhao; Haijing Wu; Yan Zhang; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-07       Impact factor: 8.667

8.  Using gene expression to improve the power of genome-wide association analysis.

Authors:  Yen-Yi Ho; Emily C Baechler; Ward Ortmann; Timothy W Behrens; Robert R Graham; Tushar R Bhangale; Wei Pan
Journal:  Hum Hered       Date:  2014-07-30       Impact factor: 0.444

Review 9.  Mouse models for Aicardi-Goutières syndrome provide clues to the molecular pathogenesis of systemic autoimmunity.

Authors:  R Behrendt; A Roers
Journal:  Clin Exp Immunol       Date:  2014-01       Impact factor: 4.330

Review 10.  Toll-like receptors: potential targets for lupus treatment.

Authors:  Yan-wei Wu; Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.